Nanexa AB (publ) announced that the recruitment and dosing has been completed in the NEX-20 Phase 1 study. Since December last year, healthy volunteers have been administered single doses in three sequential escalating dose groups. Data on the pharmacokinetic profile, safety and tolerability is now being collected for the last dose group, and results are expected to be presented after the summer.

NEX-20 is a long-acting formulation of lenalidomide based on Nanexa's drug delivery system PharmaShell. Lenalidomide is an immunomodulatory compound targeting both cancer cells and their microenvironment. Currently patients take lenalidomide daily as an oral capsule for 21-28 days in 28-day cycles.